Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing 641–660 of 2581 stories
The Agency for Toxic Substances and Disease Registry (ATSDR) is seeking public comment on the proposed National Amyotrophic Lateral Sclerosis (ALS) Registry. This initiative aims to enhance data collection efforts related to ALS, promoting better understanding and support for affected individuals.
CMS has established the Office of Rural Health Transformation within the Center for Medicaid and CHIP Services to enhance healthcare delivery in rural areas. This organizational change aims to improve access and quality of care for underserved populations.
The HHS is undergoing a review under the Paperwork Reduction Act, which may impact data collection processes. This review could affect how agencies manage paperwork and reporting requirements.
The HHS is currently undergoing a review under the Paperwork Reduction Act, which may impact data collection processes. Stakeholders should monitor developments as this could affect reporting requirements.
The National Library of Medicine has announced a partially closed meeting, which may impact future research directions and funding opportunities. Details on the agenda and participants are limited.
The National Institute of Environmental Health Sciences has announced a partially closed meeting, focusing on environmental health research. This meeting may influence future funding and research directions in the field.
The FDA has awarded national priority vouchers to two investigational products aimed at enhancing patient access through affordability. This initiative under the Commissioner’s National Priority Voucher pilot program could significantly impact pricing strategies for new therapies.
The FDA has issued a Request for Information (RFI) to gather insights from venture capital firms on a new contracting approach aimed at enhancing collaboration with innovative companies. This initiative seeks to advance public health innovation through strategic partnerships.
Emer Cooke, EMA's Executive Director, outlines the agency's goals for 2025, focusing on enhancing support for innovation in medicine regulation. The EMA aims to improve early development support for new medicines, benefiting both public and animal health.
The EMA Management Board discussed the political agreement reached among the European Commission, Parliament, and Council regarding regulatory frameworks. This meeting highlights ongoing efforts to streamline drug approval processes in the EU.
EMA will be closed for the holiday period from December 22, 2025, to January 5, 2026. This closure may affect communication and decision-making processes during this time.
FDA releases final guidance on bioresearch monitoring inspections, aligning with the Food and Drug Omnibus Reform Act of 2022. This guidance outlines the processes and practices for inspecting sites and facilities under the Bioresearch Monitoring program.
HHS proposes a rule to prohibit Medicare and Medicaid certified hospitals from performing sex-rejecting procedures on children, aiming to enhance child health and safety. This decision reflects a review of recent safety and efficacy data regarding these procedures.
The Department of Health and Human Services proposes a rule to revise nondiscrimination regulations under section 504 of the Rehabilitation Act, impacting programs receiving federal funding. This NPRM aims to enhance protections for individuals with disabilities in health-related programs.
FDA has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) under a rare pediatric disease priority review voucher. This approval highlights the agency's commitment to expedite access for treatments addressing rare pediatric conditions.
FDA has issued a priority review voucher for FORZINITY (elamipretide), a product for a rare pediatric disease, enhancing its market potential. This voucher incentivizes the development of treatments for rare conditions, aligning with FDA's commitment to expedite access for patients.
A proposed rule by HHS aims to prohibit Medicaid and CHIP funding for sex-rejecting procedures for individuals under 18. This policy could significantly impact access to care for transgender youth across states.
The HHS has rescinded the requirement for Head Start programs to implement a COVID-19 mitigation policy, as outlined in the January 2023 final rule. This change may impact operational protocols in early childhood education settings.
The FDA confirms that EFFEXOR XR (venlafaxine hydrochloride) 100 mg was not withdrawn for safety or effectiveness reasons, allowing continued approval of abbreviated new drug applications (ANDAs) referencing this product. This decision ensures ongoing market access for generic versions of the medication.
The FDA has classified the electrical tongue nerve stimulator for treating motor deficits as a Class II device, which will include special controls. This classification aims to ensure safety and effectiveness for patients with motor deficits.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.